Literature DB >> 18340393

Two decades of cardiac transplantation at the Montreal Heart Institute.

Frédéric Jacques1, Michel Carrier, Guy B Pelletier, Michel White, Normand Racine, Michel Pellerin, Denis Bouchard, Philippe Demers, Louis P Perrault.   

Abstract

BACKGROUND: The first heart transplantation in Canada was performed in 1968 at the Montreal Heart Institute (Montreal, Quebec). After nine patients transplanted in the precyclosporine era, the program was stopped. With the advent of cyclosporine, the program was reactivated in 1983.
OBJECTIVE: To review the experience of the Montreal Heart Institute with heart transplantation between 1983 and 2005.
METHODS: Three hundred patients underwent heart transplantation and were followed at the transplant clinic. Patients were divided into two groups: group 1--first decade (1983 to 1993, n=145) and group 2--second decade (1994 to 2005, n=155).
RESULTS: There were 125 men (86%) and 20 women (14%) with a mean age of 45+/-10 years in group 1 compared with 118 men (76%) and 37 women (24%) with a mean age of 48+/-12 years in group 2 (P=0.03 and P=0.02, respectively). Indications for transplantation included congestive heart failure and/or ischemic heart disease in the majority of patients of both groups, with 83% in group 1 and 73% in group 2, respectively. In group 1, 30 patients (21%) required preoperative pharmacological support and 13 patients (9%) were on mechanical support compared with 16 (10%) and 34 (22%) patients in group 2 (P<0.01). The mean age of donors was 27+/-10 years and 34+/-13 years in groups 1 and 2, respectively (P<0.01). Major causes of mortality for donors included a motor vehicle accident in 65 cases (45%) and brain hemorrhage in 43 cases (30%) in group 1 compared with 34 cases (22%) and 68 cases (44%) in group 2 donors (P<0.01). The one-, five- and 10-year actuarial survival rates were 86%, 77% and 71%, respectively, in group 1 compared with 84%, 80% and 68%, respectively, in group 2 (P=0.95). The one-, five- and 10-year freedom from rejection rates were 35%, 28% and 25%, respectively, in group 1 compared with 41%, 36% and 33%, respectively, in group 2 (P=0.13). The one-, five- and 10-year freedom from infection rates were 38%, 24% and 17%, respectively, in group 1 compared with 37%, 23% and 19%, respectively, in group 2 (P=0.72). The one- and five-year freedom from graft coronary artery disease rates were 93% and 67%, respectively, in group 1 compared with 88% and 81%, respectively, in group 2 (P<0.01). The one-, five- and 10-year cancer-free survival rates were 98%, 91% and 73%, respectively, in group 1 compared with 98%, 90% and 77%, respectively, in group 2 (P=0.76).
CONCLUSIONS: Patients who underwent heart transplantation in the second decade of the investigators' experience were older and in worse preoperative clinical condition; the donors were also older. However, survival and event-free survival rates remained similar throughout both periods.

Entities:  

Mesh:

Year:  2008        PMID: 18340393      PMCID: PMC2649637          DOI: 10.1016/s0828-282x(08)70588-9

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  19 in total

1.  Effect of recipient gender and race on heart and kidney allograft survival.

Authors:  E Reed; D J Cohen; M L Barr; E Ho; K Reemtsma; E A Rose; M Hardy; N Suciu-Foca
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

2.  Percutaneous transvenous endomyocardial biopsy in human heart recipients. Experience with a new technique.

Authors:  P K Caves; E B Stinson; M Billingham; N E Shumway
Journal:  Ann Thorac Surg       Date:  1973-10       Impact factor: 4.330

3.  The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town.

Authors:  C N Barnard
Journal:  S Afr Med J       Date:  1967-12-30

4.  Contemporary burden of illness of congestive heart failure in Canada.

Authors:  Ross T Tsuyuki; Marcelo C Shibata; Carolyn Nilsson; Marilou Hervas-Malo
Journal:  Can J Cardiol       Date:  2003-03-31       Impact factor: 5.223

5.  Effect of carvedilol on survival in severe chronic heart failure.

Authors:  M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

6.  Cardiac transplantation in patients over 50 years of age.

Authors:  M Carrier; R W Emery; J E Riley; M M Levinson; J G Copeland
Journal:  J Am Coll Cardiol       Date:  1986-08       Impact factor: 24.094

7.  Long-term results of heart transplantation in patients older than 60 years.

Authors:  Philippe Demers; Susan Moffatt; Philip E Oyer; Sharon A Hunt; Bruce A Reitz; Robert C Robbins
Journal:  J Thorac Cardiovasc Surg       Date:  2003-07       Impact factor: 5.209

8.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Clinical trial of retrograde warm blood reperfusion versus standard cold topical irrigation of transplanted hearts.

Authors:  M Carrier; T K Leung; B C Solymoss; R Cartier; Y Leclerc; L C Pelletier
Journal:  Ann Thorac Surg       Date:  1996-05       Impact factor: 4.330

10.  Effect of pravastatin on outcomes after cardiac transplantation.

Authors:  J A Kobashigawa; S Katznelson; H Laks; J A Johnson; L Yeatman; X M Wang; D Chia; P I Terasaki; A Sabad; G A Cogert
Journal:  N Engl J Med       Date:  1995-09-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.